R82
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.430
- TGF_BETA_SIGNALING+0.360
- ANDROGEN_RESPONSE+0.300
- UV_RESPONSE_DN+0.240
- G2M_CHECKPOINT+0.230
- SPERMATOGENESIS+0.190
- MTORC1_SIGNALING+0.180
- CHOLESTEROL_HOMEOSTASIS+0.160
- PANCREAS_BETA_CELLS+0.130
- MYC_TARGETS_V1+0.110
Top 10 suppressed
- MYC_TARGETS_V2-0.370
- HEDGEHOG_SIGNALING-0.330
- DNA_REPAIR-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- APICAL_SURFACE-0.270
- WNT_BETA_CATENIN_SIGNALING-0.260
- APICAL_JUNCTION-0.250
- TNFA_SIGNALING_VIA_NFKB-0.230
- UV_RESPONSE_UP-0.230
- P53_PATHWAY-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG636 | — | — | 0.795 |
| 2 | R144 | — | — | 0.767 |
| 3 | SJEPD031786_D2.RNA-Seq | EPN | Anaplastic EPN | 0.742 |
| 4 | ac295603-d08a-43f7-a78b-610be32aa49f | — | — | 0.733 |
| 5 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.729 |
| 6 | MDT-AP-0101 | Med | Medulloblastoma | 0.727 |
| 7 | R157 | — | — | 0.725 |
| 8 | R411 | — | — | 0.721 |
| 9 | SRR3147748 | — | — | 0.715 |
| 10 | SJEPD031367_D1.RNA-Seq | EPN | Anaplastic EPN | 0.707 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |